While the acquired resistance to therapy with targeted molecular therapies (i.e., mTOR inhibitors, Tyrosine kinase inhibitors) in patients with advanced panNENs/other NENs has received particular attention [6,21,29,75,77,78,81]; both primary and acquired resistance occur with the other forms of nonsurgical anti-tumor therapies in these patients to varying degrees (Figure 1). The gene discussed is MTOR; the disease is neoplasm.